Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2024-02-14 00:00:00 ET · period of report 2024-02-12 · accession 0001415889-24-003859 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-02-14 | 2024-02-12 | MLYS | Samsara BioCapital, L.P. | 10% | P - Purchase | $13.50 | +555.6K | 5.07M | +12% | +$7.50M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-12 | P | A | 555,555 | $13.50 | 5,074,916 | I See footnote | — | — | (F1) Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its pecuniary interest therein. |